The new ROI: A human-centered approach to innovation
In business, meaningful growth can't happen without innovation. But innovating for innovation's sake does not accomplish much. Instead of focusing on business transformation in a silo, it is more important than ever to identify ideas that will have a positive impact on a much larger scale.
The long-held business practice has been for innovators and decision-makers to evaluate the success of their ideas based on benchmarks in revenues, market share and product development. Equally important today are how new technologies and solutions contribute to the betterment of people, communities and the planet.
So, how can you develop new products that create a positive impact?
A key way to achieve a genuine, positive impact through product design is to prioritize a deeply human-centered approach. The needs, desires, and lived experiences of your target market must be at the forefront of every stage of design, from initial ideation to long-term implementation and beyond.
This process should involve direct engagement with the target market about the problems they're encountering and the functions they need from a solution to help solve them. Members of the market should test and provide direct feedback on prototypes and pilots, ensuring product usefulness. And to ensure a product stays valuable for the long term, there must be a plan for ongoing support for users and a way for designers to gather feedback and iterate the product as needed to meet evolving needs.
To imagine what this looks like in practice, consider a health tech startup developing an AI-powered app to help patients with chronic illnesses manage their conditions and maintain independence at home. Instead of solely focusing on the AI's capabilities, their human-centered approach would involve:
Developing a deep understanding of the challenges by spending time with people with chronic illnesses, their families, and their caregivers. This offers a fuller picture of daily struggles with medication adherence, mobility limitations, feelings of isolation, or other challenges.
Co-creating real solutions by involving these individuals in brainstorming sessions to identify features that would genuinely improve their lives. Examples could be voice-activated reminders, simplified interfaces, integrated telehealth options, personalized nutrition plans, and more.
Iterative testing provides prototypes to users within the target market. Testers should have varying levels of tech literacy so they can offer valuable feedback on accessibility and ease of use.
Establishing a dedicated support team to answer and continuously monitor user data (with their consent) to identify emerging needs and refine the app's features over time.
Similar approaches are proving invaluable across other industries as well. For example, energy innovation can benefit from a deeper understanding of the specific energy needs, motivations and financial constraints of communities. This may help lead to determining a viable approach to developing a broader array of energy options that may serve and create opportunities for economic growth by supporting the ability to build for new industries and meet the growing demand for power.
AI tools can be designed with transparency and fairness in mind by actively involving user groups from many demographics in the training and testing phases to meet the needs of all users. Mobility solutions can prioritize varying needs by incorporating feedback from different target markets, so that innovations in vehicle accessibility and transportation infrastructure deliver a positive impact for those who need it most.
No matter the application, by prioritizing the human element throughout the entire process, innovation expands beyond simple products to become valuable tools and even catalysts for widespread positive change. Beyond traditional business metrics, human-centered innovation is today's new ROI, representing a key differentiator for businesses large and small.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
America's New Anti-Vaccine Foreign Policy
The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. This week, Robert F. Kennedy Jr. used his address to a global vaccine summit to disparage global vaccination. The conference was organized by Gavi, the world's leading immunization program, and in a recorded speech, Kennedy accused the organization of collaborating with social-media companies to stifle dissenting views on immunization during the coronavirus pandemic and said it had 'ignored the science' in its work. He criticized Gavi for recommending COVID-19 shots to pregnant women, and went deep on a discredited study that purported to find safety issues with a tetanus vaccine commonly used in the developing world. 'In its zeal to promote universal vaccination,' Kennedy claimed, Gavi 'has neglected the key issue of vaccine safety.' Kennedy's remarks confirmed what The New York Times first reported in March: that the United States, Gavi's third-largest donor, would stop pledging money to the organization. (Congress, which has always had final say over Gavi funding, has not yet weighed in.) They are also the first indication that the U.S.'s rejection of global vaccine campaigns stems from the Trump administration's opposition not only to foreign aid, but to vaccination itself. For the first time, Kennedy has managed to use the anti-vaccine agenda to guide American foreign policy. Gavi, at its most basic level, is Costco for immunizations, wielding its massive purchasing power to buy vaccines in bulk for cheap. National governments and private philanthropies pledge funding to it every five years. The United Kingdom and the Gates Foundation are its largest donors; the United Nations distributes the shots. The poorest countries pay 20 cents per vaccine, and prices rise along with national income. Since the partnership was launched, in January 2000, 19 countries—including Ukraine, Congo, and Guyana—have gone from relying on Gavi to paying for vaccinations entirely on their own. Indonesia, which accepted donations from Gavi as recently as 2017, pledged $30 million to the organization this funding cycle. Gavi, by its own estimate, has saved about 19 million lives and vaccinated 1 billion children. At the conference this week, the director of the World Health Organization noted that since 2000, the number of children who die each year before they reach the age of 5 has fallen by more than half, largely due to the power of vaccines. By Gavi's estimates, the U.S. canceling its Biden-era pledge to provide $1.2 billion this donation cycle could lead to the deaths of more than 1 million children who otherwise would have lived. (The Department of Health and Human Services did not respond to a request for comment.) In his recorded remarks, Kennedy said America would not send the money until Gavi can 're-earn the public trust' by 'taking vaccine safety seriously.' Cutting off millions of children's only access to routine vaccines is 'the most emphatic globalization of the anti-vaxxer agenda,' Lawrence Gostin, the faculty director of Georgetown's O'Neill Institute for National and Global Health Law, told me. Tom Frieden, the former director of the CDC, told me that after he heard Kennedy's remarks, 'I was literally sick to my stomach,' because 'unscientific, irresponsible statements like this will result in the deaths of children.' (The U.S. has run an international anti-vaccine campaign before: According to an investigation by Reuters, in 2020, the Pentagon unleashed bot accounts on multiple social-media platforms that impersonated Filipinos and discouraged uptake of China's Sinovac vaccine—the first COVID vaccine available in the Philippines—using a hashtag that read, in Tagalog, 'China is the virus.' The goal was not to combat vaccines, but to undermine China's influence.) [Read: RFK Jr. is barely even pretending anymore] Kennedy's prerecorded address held back his harshest critiques of Gavi. In his 2021 book, The Real Anthony Fauci, Kennedy paints 'Bill Gates's surrogate group Gavi' (the Gates Foundation co-founded Gavi) as nothing more than a profiteering 'cabal' and a facilitator of 'African Genocide.' To hear Kennedy tell it, 'virtually all of Gates's blockbuster African and Asian vaccines—polio, DTP, hepatitis B, malaria, meningitis, HPV, and Hib—cause far more injuries and deaths than they avert.' Decades' worth of safety and efficacy studies have proved him wrong. In his remarks to Gavi this week, Kennedy focused on the DTP (diphtheria, tetanus, and pertussis) shot, describing at length a 'landmark' 2017 study that found the vaccine increased all-cause mortality among girls in Guinea-Bissau. But as Frieden pointed out, this was in fact a relatively small observational study. In 2022, a randomized, double-blind, placebo-controlled trial of more than 50,000 newborns found that the DTP vaccine significantly decreased infant mortality. Frieden compared the evidence: 'Hundreds of kids versus 50,000 kids. Poorly done; well done.' Kennedy made efforts to take his anti-vaccine advocacy global before he became America's health secretary. In 2021, he delivered a webinar on the importance of expanding an 'international movement' for Children's Health Defense, the anti-vaccine organization he founded. In 2019, when Samoa was experiencing a major dip in measles immunization after an improperly prepared vaccine killed two children, Kennedy visited the prime minister and, on behalf of Children's Health Defense, reportedly offered to build an information system the country could use to track the health effects of vaccines and other medical interventions. When a deadly measles outbreak took hold later that year, Kennedy sent a letter to the prime minister suggesting that widespread vaccination might make unvaccinated Samoan children more likely to die of measles. (In an interview for a 2023 documentary, Kennedy said that 'I had nothing to do with people not vaccinating in Samoa' and that his conversations about vaccines with the prime minister had been 'limited.') [Read: The U.S. is going backwards on vaccines, very fast] Now, it seems, Kennedy has gained the power to realize his ambitions both domestically and abroad. Earlier this month, Kennedy dismissed all 17 members of the CDC's vaccine advisory committee, then replaced them with a group that includes several allies who have spread misinformation about the harms of vaccines. This week, as other countries pledged their support for Gavi, Kennedy's brand-new, handpicked panel convened for a discussion of the dangers of thimerosal, a vaccine ingredient that is a frequent target of anti-vaxxers despite having been found safe. The committee has formed a working group to review the 'cumulative effect' of childhood vaccination in the United States. As Kennedy said in his address to Gavi, 'Business as usual is over.' Article originally published at The Atlantic
Yahoo
an hour ago
- Yahoo
Abbott Laboratories (ABT) Surged Ahead of the Market in 2025 with Steady Earnings Momentum
Abbott Laboratories (NYSE:ABT) is one of the Best Dividend Stocks of 2025. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. In the first quarter of 2025, the company delivered strong earnings and outperformed a group of medical device peers, despite challenging conditions driven by tariffs. The company exceeded Wall Street expectations across its three key profitability metrics: earnings per share, adjusted gross margin, and adjusted pretax income margin. It also posted stronger-than-expected organic sales growth, excluding contributions from Covid testing. During the earnings call, CEO Robert Ford noted that the diagnostics business showed solid growth in all regions except China. He mentioned that growth outside China reached about 7% this quarter and that the company is exploring opportunities in other markets to balance out the impact from China. While acknowledging current headwinds, Ford reaffirmed that China remains a valuable and profitable market for the company. Abbott Laboratories (NYSE:ABT)'s dividend policy is also very strong, making it a reliable investment option for income investors. The company is a Dividend King, having raised its payouts for 53 consecutive years. It offers a quarterly dividend of $0.59 per share and has a dividend yield of 1.77%, as of June 26. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Snapchat Shares Insight into How it Influences Consumer Electronics Purchases
This story was originally published on Social Media Today. To receive daily news and insights, subscribe to our free daily Social Media Today newsletter. Snapchat has published a new report into the role it plays in the purchase cycle for consumer electronics, based on a study of 3,000 electronics shoppers across five markets. And as you might expect (given the report was published by Snap), the data shows that Snapchat drives significant interest in electronics discovery. As per the report: 'From viral product drops to creator reviews, social platforms are a major catalyst in consumer electronics discovery. 78% of Snapchatters say social is where they typically first learn about new products and brands, which is 1.6x greater than non-Snapchatters.' Look, I'm not saying this is not true, but I do question the methodology on this one. As you can see in the examples above, the data is based on measuring how survey participants, including a subsection who identify themselves as Snapchat users, agree or disagree with each question. So the survey question would be: 'Social inspires me to find new tech products I would not have tried,' and based on how they answer, and the indicators of which apps they use, the data suggests that Snapchat users are 1.6x more likely to agree. But the results would be relative to how many Snapchat users are in the sample group, what the audience make-up is, etc. Without that data, it could be, like, 12 Snapchat users among the 3,000 total participants, which would skew the data somewhat. But even so, based on what we have here, it does seem like Snapchat users are more open to electronics discovery in the app. The data also shows that 60% of Snapchatters make purchases on social platforms directly from brand posts or ads, and 63% purchase via links on social platforms sent by friends and family. Snapchatters are also more likely to engage with brand content, and share those updates. Snapchatters are also more likely to trust influencer content: '75% of Snapchat users agree that they consider creator recommendations on social as trustworthy as those from friends and family, which is 1.8x greater than non-Snapchatters. In fact, 81% follow creators specifically for their electronics recommendations.' Finally, the report also looks at the role that AR experiences can play in electronics purchases: These are all valid points, and the methodology makes sense. But I do find it strange that all of these AR indicators are almost the exact same audience response percentage for Snapchat-specific users. That, to me, suggests that the Snapchat sample size here is relatively small, which is why it's being presented as a ratio versus other apps, as opposed to showing a percentage of total respondents. But those concerns aside, the data does suggest that Snapchat users are open to discovery and ads about consumer electronics, which could be another consideration for your marketing efforts. You can read Snapchat's full consumer electronics report here. Recommended Reading Snapchat Shares New Trend Insights and How Brands Can Tap Into Them Sign in to access your portfolio
